Should all Pima Indians with type 2 diabetes mellitus be prescribed routine angiotensin-converting enzyme inhibition therapy to prevent renal failure?

Mayo Clinic Proceedings

Volumn 74, Issue 6, 1999, Pages 559-564

  Kiberd, Bryce A ^a   Jindal, Kailash K ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; KIDNEY FAILURE; MICROALBUMINURIA; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; RETINOPATHY; SCREENING; TREATMENT PLANNING;

EID: 0033064145     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/74.6.559     Document Type: Article

References (23)

1. Ismail N, Backer B, Strzelczyk P, Ritz E. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int. 1999:55:1-28.
2. Sievers ML, Nelson RG, Knowler WC. Bennett PH. Impact of NIDDM on mortality and causes of death in Pima Indians. Diabetes Care. 1992; 15:1541-1549.
3. Gohdes D, National Diabetes Data Group. Diabetes in North American Indians and Alaska Natives. In: Diabetes in America. 2nd ed. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995:683701. NIH publication 95-1468.
4. Nelson RG, Newman JM, Knowler WC. et al. Incidence of endstage renal disease in type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia. 1988;31:730-736.
5. Bennett PH, Haffner S, Kasiske BL, et al. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis. 1995:25:107-112.
6. Morgensen CE, Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995:346:1080-1084.
7. Ravid R. Brosh D, Levi Z, Bar-Dayan Y, Ravid D. Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Ann Intern Med. 1998; 128:982-988.
8. World Health Organization Study Group. Prevention of Diabetes Mellitus. Geneva, Switzerland: World Health Organization; 1994. Technical Report Series, No. 844.
9. Siegel JE, Krolewski AS, Warram JH, Weinstein MC. Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus. J Am Soc Nephrol. 1992;3(suppl):Slll-S119.
10. Kiberd B A, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. BMJ. 1995;311:1595-1599.
11. Nelson RG, Knowler WC, Pettitt DJ, Hanson RL, Bennett PH. Incidence and determinants of elevated urinary albumin excretion in Pima Indians with NIDDM. Diabetes Care. 1995;18:182-187.
12. Kunzelman CL, Knowler WC, Pettitt DJ, Bennett PH. Incidence of proteinuria in type 2 diabetes mellitus in the Pima Indians. Kidney Int. 1989;35:681-687.
13. Nelson RG, Bennett PH, Beck GJ, et al, Diabetic Renal Disease Study Group. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. N Engl J Med. 1996;322:1636-1642.
14. Drug Topics Red Book 1997. Montvale, NJ: Medical Economics; 1997.
15. US Renal Data System. USRDS 1997 Annual Data Report. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1997.
16. Nelson RG, Hanson RL, Pettitt DJ, Knowler WC, Bennett PH. Survival during renal replacement therapy for diabetic end-stage renal disease in Pima Indians. Diabetes Care. 1996:19:1333-1337.
17. EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 1997:349: 1787-1792.
18. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. JAMA. 1996;276: 1339-1341.
19. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? tentative guidelines for using clinical and economic evaluations. CMAJ. 1992:146:473-481.
20. Lwanga SK, Lemeshow S. Sample Size Determination in Health Studies. Geneva, Switzerland: World Health Organization; 1991.
21. Johnson JA, Nowatzki TE, Coons SJ. Health-related quality of life of diabetic Pima Indians. Med Care. 1996;34:97-102.
22. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998:317:713-720.
23. Kiberd BA, Jindal KK. Routine treatment of insulin-dependent diabetic patients with ACE inhibitors to prevent renal failure: an economic evaluation. Am J Kidney Dis. 1998;31:49-54.